Finland’s updated obesity treatment guidelines will make weight-loss surgery easier to access while introducing stricter recommendations for prescribing obesity medication. The new guidance, published by the Finnish Medical Society Duodecim, also calls for a more respectful approach to treating people with obesity, moving away from attitudes that blame patients for their weight.
The updated Current Care Guidelines (Käypä hoito) set out how healthcare professionals should assess and treat obesity. They aim to improve access to bariatric surgery while discouraging doctors from prescribing weight-loss medication following brief online consultations without properly assessing patients.

Obesity remains widespread in Finland. According to the figures cited in the guidelines, approximately one in three women and one in four men have a body mass index (BMI) above the obesity threshold.
The use of obesity medication has also grown significantly. More than 100,000 people used weight-loss medication in Finland last year, according to the Social Insurance Institution of Finland, known as Kela.
One of the main changes in the updated recommendations is how healthcare professionals are expected to approach patients. Kirsi Pietiläinen, Professor of Clinical Metabolism and Chief Physician, who chaired the expert group behind the guidelines, says people with obesity should be treated with respect rather than made to feel responsible for their condition.
The recommendations encourage doctors to look beyond a patient’s weight and examine the circumstances influencing their health and eating habits. This includes their medical history, everyday life, lifestyle and personal wishes.
Instead of simply telling patients what they should eat, healthcare professionals are encouraged to understand why they eat the way they do and what makes changing their habits difficult.
Pietiläinen says this represents a move away from older approaches that focused mainly on giving patients basic dietary instructions.
“This is moving further and further away from the 1990s model, where a plate model of eating was shown and advice was given to eat this way. That is not the core of obesity treatment, but the core is understanding the person,” she says.
The guidelines also recognise that understanding the health benefits of changing eating habits does not automatically make those changes possible. Treatment should take account of the factors affecting a person’s behaviour and identify practical ways to address them.
The recommendations also introduce clearer expectations for prescribing obesity medication. Doctors are advised against issuing prescriptions through short, chat-based online consultations without a proper assessment of the patient’s health and circumstances.
Under the updated guidance, obesity medication may be considered for people with a BMI of at least 30. It may also be prescribed to those with a BMI of 27 or higher if they have additional health conditions related to obesity.
The guidelines do not recommend one particular brand or product. However, they identify semaglutide and tirzepatide as the medications supported by the strongest scientific evidence.
Semaglutide is the active ingredient in Ozempic, a diabetes medication that has also been widely used for weight loss, and Wegovy, which is specifically approved for obesity treatment. Mounjaro contains tirzepatide and is another medication used in the treatment of diabetes and obesity.
While the recommendations place greater emphasis on careful prescribing, they also make significant changes to the criteria for bariatric surgery.
Previously, patients generally had to lose at least five per cent of their body weight before they could be referred for specialised medical assessment. That requirement has now been removed.
Instead, patients must first undergo approximately six months of basic obesity treatment through healthcare services. This can include lifestyle counselling and medication. If these measures do not produce sufficient weight loss or health benefits, bariatric surgery can then be considered.
The BMI threshold for surgery has also been lowered. Under the new recommendations, patients with a BMI of 35 may qualify for surgery, compared with the previous threshold of 40. For people with poorly controlled type 2 diabetes, surgery may be considered at a BMI of 30 to 35.
The guidelines also recommend an upper age limit of under 65 for bariatric surgery. Pietiläinen says the changes reflect developments in international recommendations on surgical treatment for obesity.
ALSO READ: Young Finns Want a Political Party of Their Own as Dissatisfaction with Established Parties Grows
The revised guidelines are also intended to make treatment decisions easier for healthcare professionals. They provide more practical instructions than the previous recommendations and include printable information sheets that doctors and other healthcare workers can use during appointments or give directly to patients.
However, the guidance may not remain unchanged for long. Research into obesity medication continues to develop, and questions remain about the long-term effectiveness and safety of these treatments. Pietiläinen notes that the medications have only been available for around a decade, meaning evidence about their effects over longer periods is still limited.
The updated recommendations therefore seek to balance access to treatment with careful medical assessment, while placing greater emphasis on understanding the individual circumstances of people living with obesity.


